Olan Adverse Reactions

Frequent (>10%): Somnolence and weight gain are the only frequent undesirable effects associated with the use of Olan. Weight gain is related to a lower pre-treatment body mass index (BMI) and initial starting dose of ≥15 mg.
Occasional (1-10%): Dizziness, increased appetite, peripheral oedema, orthostatic hypotension, and mild, transient anticholinergic effects including constipation and dry mouth are the occasional undesirable effects associated with the use of Olan.
Transient, asymptomatic elevations of hepatic transaminases, ALT, AST have been seen occasionally, especially in early treatments.
Although in various studies, Olan-treated patients had a lower incidence of parkinsonism, akathisia and dystonia compared with titrated doses of haloperidol. In the absence of detailed information on the preexisting history of individual acute and tardive extrapyramidal movement disorders, it can not be concluded at present that Olan produces less tardive dyskinesia and/or other tardive extrapyramidal syndromes.
Rare (<1%): Rarely, photosensitivity reaction has been reported.
Other Findings: Plasma prolactin levels were sometimes elevated, but associated clinical manifestations (eg, gynaecomastia, galactorrhoea and breast enlargement) were rare. In most patients, levels returned to normal ranges without cessation of treatment.
High creatine phosphokinase levels have been observed in rare cases.
As with other neuroleptic drugs, asymptomatic haematologic variations were occasionally seen.